Clinical Trials Logo

Pancreas Neoplasm clinical trials

View clinical trials related to Pancreas Neoplasm.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06381882 Not yet recruiting - Pancreas Cancer Clinical Trials

The Role of the Human Microbiome in Patients After Pancreatic Resection.

MiPac
Start date: May 1, 2024
Phase:
Study type: Observational

The goal of this observational study is to classify patients that undergo pancreatic resection for presumed pancreatic or periampullary malignancy into high and low risk groups for postoperative complications based on longitudinal saliva, rectal/faecal, tumor, blood and/or bile microbiome profiles. To identify the dynamics of the microbiome, as well as the possibly related short-term and long-term complications, multiple samples at different timepoints are needed from the patients.

NCT ID: NCT05463328 Not yet recruiting - Pancreas Neoplasm Clinical Trials

Open Versus Laparoscopic Assisted Pancreaticoduodenectomy

Start date: December 1, 2022
Phase: N/A
Study type: Interventional

Compare open and laparoscopic assisted pancreaticoduodenectomy regarding intraoprative blood loss, organ injury, completion of planned laparoscopic steps, duration and early post operative course of pain, hem stability, oral feeding, leakage(pancreatic, billary and intestinal). ,bleeding, mortality, lymph nodes and safety margins .

NCT ID: NCT04768660 Not yet recruiting - Pancreas Neoplasm Clinical Trials

Effects of Chewing Gum Against Postoperative Ileus

Start date: February 14, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether the use of chewing gum effects postoperative ileus after pancreaticoduodenectomy

NCT ID: NCT04336839 Not yet recruiting - Clinical trials for Neuroendocrine Tumors

Portal Vein Resection in Pancreatic Neuroendocrine Tumours

PVNET
Start date: May 1, 2020
Phase:
Study type: Observational

The limited evidence on the value of portal vein resection in patients with borderline resectable and/or locally advanced PanNENs is an incentive to carry out a retrospective multicentre study amongst centres with specific interest in the management of PanNENs and with experience on vascular reconstruction. Unlike previous studies on pancreatic cancer, it is more difficult to standardise the comparative parameters as the definition of borderline resectable disease has never been published for PanNENs. Similarly, different histological classifications make impossible to collect data exclusively on T3 tumours. Therefore, we aim to compare the short and long-term outcomes (including the impact of the histological depth of vascular invasion on survival) between patients undergoing standard PD and PD with portal vein resection for PanNENs, (regardless of T stage), by collecting and analysing retrospective data in this single centre study